TITLE

Alcon Paying Up to $589M for EsbaTech Eye Business

PUB. DATE
September 2009
SOURCE
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the acquisition of ESBATech AG by Alcon Inc. in Hunenberg, Switzerland. It states that Alcon will acquire the ophthalmology business for 589 million dollars and that ESBATech's other programs will be spun off into a new firm, Delenex Therapeutics AG. It adds that the EsbaTech is committed in making drugs based on single chain antibody.
ACCESSION #
44369826

 

Related Articles

  • Alcon Paying Up to $589M for EsbaTech Eye Business. Sheridan, Cormac // BioWorld Today;9/15/2009, Vol. 20 Issue 177, p1 

    The article reports on the acquisition of the ophthalmology business of ESBATech AG by Alcon Inc. The deal does not include the programs of ESBATech in areas outside ophthalmology, which are being spun out into Delenex Therapeutics AG. ESBATech is a privately held company which develops drugs...

  • Alcon Paying Up to $589M for EsbaTech Eye Business. Sheridan, Cormac // BioWorld International;9/16/2009, Vol. 14 Issue 37, p1 

    The article reports on the decision of Alcon Inc. to acquire the ophthalmology business of ESBATech AG. It explores the value and coverage of the acquisition deal. A brief overview is given on the business operation of both biotechnology companies. It also discusses the purpose of Alcon's entry...

  • Biotechnology News Round-Up.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p30 

    The article offers news briefs related to biotechnology industries. The Genetech Inc. encourages data from its clinical study Ribbon 2 which tests on avastin and chemotherapy as treatment for breast cancer. Novartis AG and UCB Inc. has agreed to license cardiovascular and diabetes products to...

  • Alcon to pay up to $589M for Swiss biotech firm ESBATech.  // Medical Device Daily;9/15/2009, Vol. 13 Issue 177, p2 

    The article reports on the agreement of Alcon to acquire ESBATech, a Swiss biotechnology company, for 598 million U.S. dollars in cash and contingent payments. Under the deal, Alcon will gain all rights to ESBATech's technology for therapeutic application to the eye, and employees of ESBATech...

  • INDUSTRY NEWS IN BRIEF.  // Ocular Surgery News;10/25/2009, Vol. 27 Issue 20, p94 

    This section offers news briefs related to the ophthalmic industry. PresbyMax, a presbyopia-correcting software for excimer laser, has been introduced by Schwind eyetech-solutions. Alcon released a report announcing its plan to acquire Swiss biotechnology company ESBATech. A pharo combined...

  • complete merger, plan transformation. Webb, Jennifer A. // Ophthalmology Times;5/1/2011, Vol. 36 Issue 9, p1 

    The article focuses on the acquisition of eye care company Alcon Inc. by Novartis AG. It states that Alcon's business will merge with Novartis to become the second-largest division in Novartis' profile. Further it mentions that Alcon will realign its business units into three separate divisions...

  • INDUSTRY NEWS IN BRIEF.  // Ocular Surgery News Europe;Sep2009, Vol. 20 Issue 8, p34 

    This section offers news briefs on the ophthalmology sector. A 13th branch was opened by World Eye Centers in Ankara, Turkey to serve the Anatolia region. Alcon has started construction of its first pharmaceutical manufacturing plant in the Asian region at the Singapore Tuas Biomedical Park....

  • Novartis and Alcon Complete Merger.  // Review of Ophthalmology;Jan2011, Vol. 18 Issue 1, p4 

    The article reports on the completion of the merger between Novartis AG and Alcon Inc. to create a broader commercial capabilities in eye-care business.

  • Independent analysis questions the adequacy, legality of Novartis' merger proposal to Alcon.  // Ocular Surgery News;3/25/2010, Vol. 28 Issue 6, p39 

    The article reports on an analysis by RiskMetrics Group, which criticizes the adequacy and legality of Novartis' proposed merger with Alcon.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics